No Prevention — Full HPV and Cancer Risk
No vaccine, no screening — infection and progression proceed unchecked.
- 80%: HPV lifetime exposure (of sexually active adults)
- 14: High-risk HPV types (linked to cervical cancer)
- 10–20 yrs: Progression window (infection to invasive cancer)
- 350k: Annual global deaths (cervical cancer mortality)
Unblocked infection
HPV enters cervical cells freely with no immune priming.
Silent progression
Dysplasia advances undetected with no screening safety net.
Late-stage discovery
Cancer is often found only after symptoms appear.
Vaccination Only — Infection Blocked, No Safety Net
Vaccine blocks covered strains, but the screening gap stays open.
- ~90%: Vaccine efficacy (against covered HPV strains)
- 9: Strains covered (nonavalent vaccine)
- 0%: Screening active (no cytology performed)
- uncovered types: Breakthrough exposure (still fully unprotected)
Outer shield active
Antibodies neutralize HPV before cervical cell entry.
Coverage gap
Non-vaccine strains can still infect and progress silently.
No detection layer
Any breakthrough disease goes uncaught without screening.
Screening Only — Unvaccinated but Monitored
No vaccine, but Pap cytology catches dysplasia before cancer forms.
- ~75%: Pap sensitivity (per single screening round)
- 0%: Infection prevention (no vaccine layer present)
- adherence: Detection driver (attendance sets capability)
- CIN2/3: Treatable precancer stage (caught before invasion)
No outer shield
HPV infects freely with no vaccine block in place.
Inner shield engaged
Cytology screens catch abnormal cervical cells.
Adherence dependent
Detection power scales directly with screening attendance.
Vaccination Plus Screening — Two Independent Layers
Infection is blocked and any residual disease is caught early.
- ~98%: Combined protection (two independent layers multiplied)
- ~90%: Infection prevention (vaccine layer)
- adherence-scaled: Early detection (screening layer)
- <5%: Residual risk (rare breakthrough cases only)
Outer shield first
Vaccination stops most infections before they start.
Inner shield backup
Screening catches whatever breakthrough infection remains.
Independent layers multiply
Combined protection exceeds either layer used alone.
Maximal Protection — Full Two-Layer Coverage
High vaccination and full screening adherence minimize cancer risk.
- ~99%: Combined protection (at full adherence)
- ~1–2%: Residual cancer risk (irreducible minimum)
- millions: Lives saved potential (with global scale-up)
- 90-70-90: WHO elimination target (vaccination-screening-treatment goals)
Full outer coverage
Nearly all vaccine-preventable infections are stopped outright.
Full inner coverage
Consistent screening catches nearly all residual disease early.
Near-elimination state
Together the layers approach cervical cancer elimination targets.